12 million people are affected by Hepatitis C in India. India is one of the few countries in the world which have generics for interferon – free treatment, to help combat the disease. Also, fresh hope to patients as the Apex Committee of the Central Drugs Standard Control Organisation (CDSCO), has granted a waiver of local trials for crucial new direct-acting antiviral drugs sofosbuvir and ledipasvir for treatment of Hepatitis C. This is expected to bring down the costs of the generic drugs within weeks. The union health ministry of India is also planning to make a mandatory system of prescribing drugs with their generic names.
Where the treatment costs over US $90,000 in the US and US $60,000 in the EU, it is expected to cost US $1000 or less in India due to the availability of generics. To know more about the treatments available in India and their costs – refer to The Holiday Healer Treatment Cost Comparison Page.
It is expected to revolutionize the treatment of Hep C similar to that the Indian generics contributed to AIDS/HIV treatment. Currently medical tourism in this sector is strong and has managed to help patients from all across the world.
Sofosbuvir was registered in India in January 2015 and daclatasvir was registered this month (More Statistics about Registration in India). The combo is seen as a very potent cure with about 90% cure rate and for no other disease has such a short-time cure become available, that too in a generic version.
Other News
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read More
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
TUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More
